Macular degeneration (age-related) - photodynamic therapy (TA68)
Fast, easy summary view of NICE guidance on 'eye conditions '
The clinical effectiveness and cost effectiveness of photodynamic therapy for age-related macular degeneration
NICE has made the following recommendations about the use of photodynamic therapy (PDT) to treat age-related macular degeneration (ARMD).
NICE recommends PDT for people with wet ARMD who have a confirmed diagnosis of classic subfoveal choroidal neovascularisation (CNV), with no sign of occult CNV. People should also have at least 6/60 vision – this means that they can see (with glasses if they usually wear them) the same line of test letters 6 metres away that a person with normal vision can see when 60 metres away.
PDT treatment should be carried out by doctors who specialise in treating disorders of the retina and who have experience in using PDT.
PDT is not recommended for people who have wet ARMD with mostly classic subfoveal CNV (that is, at least half is classic but there is also some occult CNV). The exception is where the person is treated as part of a clinical study designed to provide useful information on the effectiveness of the treatment.
NICE has not made any recommendations about PDT for people who have ARMD with occult CNV. This is because, when the appraisal process started, the light-sensitive substance was not licensed to be marketed or prescribed for occult CNV in the UK. (This is because its 'marketing authorisation', which is normally needed before a medicine can be marketed or prescribed, did not cover patients with occult CNV. The process of giving a medicine its marketing authorisation is not related to the NICE appraisal process and it is not carried out by NICE. Further information on this is available from the Medicines and Healthcare products Regulatory Agency (MHRA).
Everyone with ARMD who started a course of PDT on the NHS before the NICE guidance was issued should have the option of continuing the course until their clinical condition indicates that it is appropriate to stop. This may be judged by the effects of PDT on the results of fluorescein angiography and the rate of loss of vision.
Additional funding information for this guidance can be found on the Department of Health website.
- TA68 Macular degeneration (age related) - photodynamic therapy: guidance (web format)
- TA68 Macular degeneration (age related) - photodynamic therapy: summary
- TA68 Macular degeneration (age related) - photodynamic therapy: questions and answers
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: eye conditions
- TA68 Macular degeneration (age-related) - photodynamic therapy: review update - June 2012
- Review update - October 2011
- Clinical effectiveness and cost utility of photodynamic therapy for wet age-related macular degeneration
- NICE guidance sets recommendations on photodynamic therapy for age-related macular degeneration
- Review decision
- Review proposal
This page was last updated: 22 November 2013
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.